Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma…
Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal…
CF Industries reported second-quarter results that were generally in line with analysts’ expectations. Nitrogen volumes were up 2.2% year over year as the nitrogen application season in North America finished at a rapid pace following delays to planting caused by wet weather in the Corn Belt. Last season, warm weather in the spring pulled planting…
Parker Hannifin delivered fourth-quarter earnings of $1.78 per diluted share, resulting in full-year earnings of $6.26 per share. Both metrics were below our expectations as sluggish global demand in Parker’s end markets continues to stunt revenue growth. Additionally, the company has struggled to keep margins flat, which amplifies the impact on earnings. For 2014, the…
Tourmaline Oil reported second-quarter results after the market closed on Friday. Despite weatherrelated setbacks, the company still increased production, and has now set the stage to deliver phenomenal growth in the second half of the year. Results for the quarter lined up with expectations. Production averaged 70.1 thousand barrels of oil equivalent per day versus…
Shares of Sunesis Pharmaceuticals, Inc (SNSS) plunged significantly after the company announced that its phase III trial, VALOR, failed to meet its primary endpoint. The randomized, double-blind, placebo-controlled trial (n=711) evaluated the efficacy of Qinprezo (vosaroxin) and cytarabine in patients suffering from first relapsed or refractory acute myeloid leukemia (AML). The trial failed to reach…
